| 50th week of 2008 patent applcation highlights part 33 |
| Patent application number | Title | Published |
|---|
| 20080305045 | Methods of synthesis of non-toxic multifunctional nanoparticles and applications - The present invention involves multifunctional nanoparticle dispersions and methods for making them using sol-gel chemistry, doping, and sonication. These methods avoid the high thermal budget processes of the reference art. The dispersions can accommodate greater concentrations of nanoparticles, dopants, and ions than has previously been possible since these components can be added during synthesis. The unique optical, magnetic, luminescent, metallic, insulating, semi-conducting, and/or conducting properties of these particles can be utilized to enhance photovoltaic cells, portable electronic devices, and biomedical techniques among other applications. | 2008-12-11 |
| 20080305046 | MOLECULAR IMAGING METHODS FOR DIAGNOSIS AND EVALUATION OF OCULAR AND SYSTEMIC DISEASES - This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and leukocyte antigens that are predictive of diabetic retinopathy (DR) and/or other conditions using protein-conjugated microparticles detectable by a non-invasive detection system, for example, a scanning laser opthalmoscope. In other embodiments, the invention relates to targeted delivery of drugs or other substances to specific regions of an intraluminal surface of a blood vessel using drug-containing microparticles coated with one or more ligand binding partners. | 2008-12-11 |
| 20080305047 | Chemosensors Based on Quantum Dots and Oxazine Compounds - We identified a mechanism to detect chemical changes with a modified semiconductor nanoparticle (e.g., an oxazine-adsorbed CdSe—ZnS core-shell quantum dot). Our strategy is based on the chemical transformation of chromo-genie ligands adsorbed on the surface of a quantum dot. This activates an energy transfer pathway from the quantum dot to the adsorbed chromogenic ligands, which causes a change (e.g., increase or decrease) in a characteristic of fluorescent emission (e.g., intensity or lifetime). Thus, modified quantum dots acting through this mechanism can efficiently transduce a chemical event or occurrence into a change in optical signal. Our design can be adapted to signal chemical changes by a diversity of target analytes and, thus, it can be used to develop other fluorescent chemosensors based on the unique properties of quantum dots. | 2008-12-11 |
| 20080305048 | Self-Assembling Nanoparticle Conjugates - This invention relates to magnetic nanoparticle conjugates and related compositions and methods of use. | 2008-12-11 |
| 20080305049 | Mri Contrast Agents for Diagnosis and Prognosis of Tumors - The invention relates to bifunctional conjugates comprising a receptor ligand moiety and a metal binding moiety and complexes thereof with paramagnetic lanthanide or transition metals, and to the use of the metal complexes as contrast agents in magnetic resonance imaging (MRI) of tumors and other abnormalities. | 2008-12-11 |
| 20080305050 | Analysis of P. aeruginosa infection in patients - The present invention relates to methods for detecting | 2008-12-11 |
| 20080305051 | Menthane Carboxamide Derivatives Having Cooling Properties - A compound of the formula I | 2008-12-11 |
| 20080305052 | Use of Hesperetin for Enhancing the Sweet Taste - The use of hesperetin of formula (I) is described wherein the hesperetin of formula (I) is in the form of a (2S)-enantiomer, (2R)-enantiomer or any desired mixture of the two enantiomers, a salt of hesperetin of formula (I), —a mixture comprising or consisting of two or more salts of the hesperetin of formula (I), or a mixture comprising or consisting of hesperetin of formula (I) and one or more salts of hesperetin of formula (I) for enhancing the sweet taste of a sweet-tasting substance or sweet olfactory impression of a flavouring which gives a sweet olfactory impression. | 2008-12-11 |
| 20080305053 | Fluoride-releasing strips for tooth - The present invention discloses fluoride-releasing strips for tooth, wherein the fluoride-releasing strips comprises a fluoride-containing solution for releasing fluorine ion and a support substrate. A formula of fluoride-containing solution comprises a fluoride solution, at least one buffer, at least one moisturizer and a tackiness agent. The support substrate is waterproof material and a fluoride-containing solution is applied on the support substrate. | 2008-12-11 |
| 20080305054 | Use of Glycosylated Flavanones for the Browning of Skin or Hair - The use of a compound having formula (I) is described as an agent for the browning of skin or hair, Formula (I) wherein: R1 and R2 are mutually independently H, OH, C1-C10-alkyl, C1-C10-O-alkyl or O-prenyl, R3 is H, OH, O-glucose or O-rhamnose and R4 is a monosaccharide radical or an oligosaccharide radical having 2, 3, 4 or 5 carbohydrate units, with the proviso that the compound having formula (I) is not used in the form of a preparation based on | 2008-12-11 |
| 20080305055 | Anti-Radical Agents - Compounds of the formulae (1), (2) and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of formula (3), wherein Gi is hydrogen; C | 2008-12-11 |
| 20080305056 | STABLE, LOW VISCOSITY COSMETIC COMPOSITIONS - The invention relates to a cosmetic composition for application to the skin, having:
| 2008-12-11 |
| 20080305057 | New and improved skin treatment systems - A basic facial and body treatment cosmetic formulation is a combination of a cationic emulsifying agent, an oil soluble liquid polymer and a naturally occurring lactate buffer system. The basic formulation is a starter system that can be specialized to skin moisturizers, skin lighteners, skin pigmenting agents, sunscreens, antioxidants, line reducing products, wrinkle reducing products, anti-cellulite products, pharmaceuticals and the like. | 2008-12-11 |
| 20080305058 | Photoprotective cosmetic compositions comprising photostabilized dibenzoylmethane compounds and merocyanine sulfone compounds - Photostable, topically applicable cosmetic/dermatological compositions contain at least one dibenzoylmethane compound UV-A sunscreen and at least one merocyanine sulfone compound. | 2008-12-11 |
| 20080305059 | Skin lightening compositions and methods - Skin lightening/even toning compositions are provided for reducing skin pigmentation of normal skin and for lightening hyper-pigmented skin said compositions comprising (i) highly purified hexylresorcinol which is substantially free or resorcinol, (ii) optionally, at least one other skin lightening agent, and (iii) a dermatologically acceptable carrier. | 2008-12-11 |
| 20080305060 | AQUEOUS-ALCOHOLIC DEPIGMENTING GELS - Stable, topically applicable cosmetic/pharmaceutical skin depigmenting compositions contain at least one phenolic compound, at least one retinoid and at least one corticoid, and are formulated as aqueous-alcoholic gels in topically applicable, physiologically acceptable media therefor. | 2008-12-11 |
| 20080305061 | Comfortable transfer-resistant colored cosmetic compositions containing a silsesquioxane wax - The present invention is directed to a composition containing: (a) at least one propylsilsesquioxane wax substituted with alkyl units having at least 30 carbons; (b) a liquid fatty phase; (c) at least one emulsifier chosen from an emulsifying silicone elastomer; (d) at least one colorant; (e) water; and (f) optionally, at least one film forming resin chosen from a propylphenylsilsesquioxane resin having a molecular weight of from about 2,000 to about 30,000 and comprising at least about 70 mole % propyl siloxy units, based on the total mole % siloxy units of the resin, and at most about 30 mole % phenyl siloxy units, based on the total mole % siloxy units of the resin, and a silicone acrylate copolymer resin. Also disclosed is a method of making up skin involving applying the above described composition onto the skin. | 2008-12-11 |
| 20080305062 | Cosmetic compositions containing a propylphenylsilsesquioxane resin and a cosmetically-acceptable aromatic solvent - The present invention is directed to a cosmetic composition containing: (a) at least one propylphenylsilsesquioxane resin; (b) at least one cosmetically-acceptable aromatic solvent; (c) at least one colorant, and (d) optionally, at least one co-solvent, and wherein the composition is substantially free of volatile solvents. Also disclosed is a method of imparting lasting shine onto lips by contacting the lips with the above described composition. | 2008-12-11 |
| 20080305063 | 1-aza-3,7-dioxabicyclo[3.3.0]octane compounds and their use as pro-fragrances - 1-aza-3,7-dioxabicyclo[3.3.0]octane compounds, process for their preparation, their use as pro-fragrances, and washing and cleaning compositions, fabric softeners and cosmetics comprising them, and a process for prolonging the odor perception of such compositions. | 2008-12-11 |
| 20080305064 | Hair styling compositions containing a combination of a propylphenylsilsesquioxane resin and a phenylsilsesquioxane resin - A process of styling hair involving applying onto the hair a composition containing: (a) at least one propylphenylsilsesquioxane resin comprising from about 30 to about 50 mole % of propyl siloxy units, based on the total mole % of siloxy units of the resin, and from about 50 to about 70 mole % of phenyl siloxy units, based on the total mole % of siloxy units of the resin; (b) at least one phenylsilsesquioxane resin; (c) at least one volatile solvent; and (d) optionally, at least one cosmetically-acceptable aromatic solvent. | 2008-12-11 |
| 20080305065 | Novel polysiloxanes having quaternary ammonium groups, a process for the preparation thereof and the use thereof in cleaning and care formulations - The invention relates to polysiloxanes of the general formula (I) | 2008-12-11 |
| 20080305066 | 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour - Use of a compound of formula 1 as malodour neutraliser | 2008-12-11 |
| 20080305067 | Comfortable, long wearing colored cosmetic compositions - The present invention is directed to a composition containing: (a) at least one tackifier component having a glass transition temperature (T | 2008-12-11 |
| 20080305068 | Cosmetic compositions having improved transfer resistance - Cosmetic compositions and methods with improved transfer resistance and long wear properties are disclosed. The cosmetic compositions contain a synergistic combination of at least one silicone polyurethane polymer and at least one elastomer. | 2008-12-11 |
| 20080305069 | Cosmetic Use of Tensing Agents to Improve the Thickness of the Skin and/or the Radiance of the Complexion - The invention relates in particular to the cosmetic use of a composition containing, in a physiologically acceptable medium, an effective amount of at least one mosaic-effect tensing agent for improving the thickness of the skin and/or promoting the radiance of the complexion. The invention also relates to the cosmetic use, in a composition containing a physiologically acceptable medium, of an effective amount of at least one mosaic-effect tensing agent as an agent intended to improve the firmness and/or elasticity and/or tonicity of the skin. The invention likewise relates to a cosmetic method of treatment of dull and/or poorly defined complexion that comprises the topical application of a composition comprising at least one mosaic-effect tensing agent to people who have a dull and/or poorly defined complexion. Mosaic-effect agents of this kind are selected in particular from (i) mineral tensing agents and (ii) tensing polymers. | 2008-12-11 |
| 20080305070 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS - Activated polymeric bicine derivatives such as, | 2008-12-11 |
| 20080305071 | Surface Cleaning Method and Composition - The present disclosure provides a method for treating a contaminated surface. According to one embodiment of the present disclosure, the method preferably includes a first step of providing a cleaning composition which includes from about 0.002 to about 2 percent, by weight, of a cationic surfactant which is capable of acting as a microbial biocide and from about 0.05 to about 5 percent, by weight, of a boron-containing component which is capable of acting as both a microbial biostat and an insecticide. This cleaning composition is applied to the surface so as to substantially remove contaminants from the surface while, leaving a residual amount of the cleaning composition on the surface to act as a biostat. The surface is then allowed to become at least partially recontaminated so that contaminants contact on the surface and mix with the residual cleaning composition on the surface to form an insecticidal bait effective to attract insects such that the insects ingest the insecticidal bait and die as a result. A cleaning composition is also disclosed. | 2008-12-11 |
| 20080305072 | Attractant for the Anastrepha Obliqua Fruit Fly - The invention relates to a specific attractant for male and female | 2008-12-11 |
| 20080305073 | Therapeutic Agents for the Treatment of Hmgb1-Related Pathologies - The present invention relates to the use of synthetic double-stranded nucleic acid or nucleic acid analogue molecules with a bent shape structure for the prevention and treatment of pathologies induced directly or indirectly by the HMGB1 protein. | 2008-12-11 |
| 20080305074 | Stem cell factor - Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed. | 2008-12-11 |
| 20080305075 | Treatment of Hyperproliferative Diseases with Vinca Alkaloid N-Oxide and Analogs - The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders. | 2008-12-11 |
| 20080305076 | METHOD OF INDUCING MEMORY B CELL DEVELOPMENT AND TERMINAL DIFFERENTIATION - A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. In one embodiment, the B cell progenitor is an immature B cell. A method is also disclosed for enhancing an immune response. The method includes contacting a population of cells including a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. The memory B cells and/or the plasma cell are then introduced into the subject to enhance the immune response. A method is also disclosed for treating a subject with a condition comprising a specific deficiency of at least one of memory B cells and plasma cells. A method is disclosed for identifying an agent with a physiological effect on one or more of a memory B cell and a plasma cell differentiation. A method is also disclosed for identifying agents that inhibit an activity of IL-21. Methods are also disclosed for inducing apoptosis of a B cell and for decreasing the number of B cells. A method is also described for producing a B cell hybridoma. | 2008-12-11 |
| 20080305077 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ENHANCING TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM - Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to, inter alia, the CNS applied via intranasal administration while reducing non-target exposure are provided. In certain embodiments, at least one vasoconstrictor is provided intranasally prior to intranasal administration of at least one therapeutic compound. In other embodiments, the vasoconstrictor(s) and therapeutic compound(s) are combined in a pharmaceutical composition and delivered intranasally. The present invention substantially increases targeting of the therapeutic compound(s) to, inter alia, the CNS while substantially reducing unwanted and potentially harmful systemic exposure. The preferred administration of the invention applies the vasoconstrictor(s) and/or therapeutic compound(s) to the upper third of the nasal cavity, though application to the lower two-thirds of the nasal cavity is also within the scope of the invention. | 2008-12-11 |
| 20080305078 | Soluble Il-17Rc Variant and Uses Thereof - The present invention relates to a new soluble IL-17RC variant and its therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders or neurological diseases. | 2008-12-11 |
| 20080305079 | Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity - The present invention relates to novel myeloid suppressor cells (MSCs) and to methods of isolating these MSCs are also included. The MSCs of the present invention can be used to treat or prevent autoimmune diseases or alloimmune responses. The MSCs of the present invention may also be used to reduce a T cell response, induce T regulatory cells, and produce T cell tolerance. | 2008-12-11 |
| 20080305080 | RECOMBINANT SUPER-COMPOUND INTERFERON - This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods to produce recombinant super-compound interferon or its equivalent and various uses of said interferon. | 2008-12-11 |
| 20080305081 | Novel aminopyrimidine derivatives as PLK1 inhibitors - The present invention relates to a compound represented by Formula [I]: | 2008-12-11 |
| 20080305082 | 1,4-Bis-N-Oxide-5,8- Dihydroxyanthracenedione Compounds and the Use Thereof - Disclosed are compounds having Formula I: and pharmaceutically acceptable salts thereof, wherein R | 2008-12-11 |
| 20080305083 | GFAP-BASED GENE THERAPY FOR TREATMENT OF RETINAL DISEASES - Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid constructs and vectors. | 2008-12-11 |
| 20080305084 | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions - The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved. | 2008-12-11 |
| 20080305085 | Compositions And Methods For Stem Cell Expansion - The present invention features methods and compositions that are useful for promoting stem cell survival and expansion. In addition, the invention also provides compositions and methods for the treatment of neoplasia. | 2008-12-11 |
| 20080305086 | HUMAN LATE STAGE MOTOR NEURON PROGENITOR CELLS AND METHODS OF MAKING AND USING SAME - Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of making and using the same, including deriving late stage MNP cells from pluripotent embryonic stem cells, producing high-purity populations of late stage MNP cells, producing populations of viable MNP cells, transporting viable MNP cells, and transplanting MNP cells. | 2008-12-11 |
| 20080305087 | Device and Method Using Integrated Neuronal Cells and an Electronic Device - The present invention provides a device of integrated neuronal cells interfaced with an electronic device and a method of producing the same. | 2008-12-11 |
| 20080305088 | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy - A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth. | 2008-12-11 |
| 20080305089 | Pharmaceutical Composition for Protection from Allergies and Inflammatory Disorders - The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of | 2008-12-11 |
| 20080305090 | COMPOSITION FOR PROMOTING THE PROLIFERATION OF LACTOBACILLUS CASEI SUBSP. CASEI - A composition for promoting bacterial proliferation and selectively proliferating | 2008-12-11 |
| 20080305091 | Poly-Epitope Peptide Derived from Thymidylate Synthase Having Immunological and Anti-Tumour Activity - The present invention concerns a peptide having anti-tumour activity and its related pharmaceutical compositions. In particular, the invention concerns a peptide with anti-tumour preventive and therapeutic activity, also in combination with other known anti-tumour compounds such as, for example, 5-fluorouracil. | 2008-12-11 |
| 20080305092 | Methods of treating autoimmune disease via CTLA-4IG - The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects. | 2008-12-11 |
| 20080305093 | Liquid Formulations of Carboxamide Arthropodicides - Disclosed are suspension concentrate compositions comprising by weight based on the total weight of the composition, about 0.1 to about 40% of at least one carboxamide arthropodicide; 0 to about 20% of at least one other biologically active agent; about 30 to about 95% of at least one water-immiscible liquid carrier; about 2 to about 50% of at least one emulsifier; about 0.01 to about 10% of a silica thickener; about 0.1 to about 10% of at least one protic solvent selected from water, a C | 2008-12-11 |
| 20080305094 | Nutritional Composition for Improving Skin Condition and Preventing Skin Diseases - The present invention pertains to the use of an ingestable composition containing L-carnitine and at least one component having an anti-oxidative activity for stimulating the lipid metabolism in the skin of an individual, which results in an improvement of the general condition of the skin in particular dry, sensible or reactive skin, and in prevention of the occurrence of skin diseases, such as dermatitis. In addition thereto, the present invention pertains also to the use of such a composition for the preparation of a pharmaceutical composition or of a food, in particular a functional food or petfood product, for increasing lipid secretion in sebum, producing a protective sebum layer on the skin. | 2008-12-11 |
| 20080305095 | Nutritional Drink - A first composition of drink ingredients specifically designed to lower cholesterol that addresses multiple mechanisms including hepatic synthesis and release, intestinal absorption of cholesterol, while, at the same time, including ingredients that mitigate the side effects of the constituents and increase their efficacy by affecting emotional factors that influence compliance such as a sense of well-being and euphoria on the one hand, or an increased overall metabolism and desire for the product stemming from its coloration on the other hand. | 2008-12-11 |
| 20080305096 | METHOD AND COMPOSITION FOR PROVIDING CONTROLLED DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES - A method of providing controlled release of a biologically active substance within a subject's digestive system. The biologically active substance is administered concurrently with one or more soluble fibers in an oral dosage unit. The soluble fibers interact with the biologically active substance within the subject's digestive system to moderate and control the release of the biologically active substances in the subject's bloodstream. This provides more constant blood concentrations of the biologically active substances. The amount of soluble fibers in the oral dosage unit is greater than 40% by weight, and in some cases greater than 50% by weight of the oral dosage unit. The oral dosage unit typically contains from about 1 to 15g of soluble fiber, and in some cases from about 3 to 5g of soluble fiber. The biologically active substance may contain phytonutrients that promote the subject's cardiovascular system, immune system, or weight management. | 2008-12-11 |
| 20080305097 | Use of Protease or a Protease Inhibitor for the Manufacture of Medicaments - The invention relates to the use of a cathepsin K inhibitor (CTKI) or CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof in the manufacture of a medicament for treating a disease in which SDF-1 activity and/or concentration is involved with the development and/or course of the disease. | 2008-12-11 |
| 20080305098 | Recombinant Polypeptides and Methods for Detecting and/or Quantifying Autoantibodies Against Tsh Receptor - The present invention relates to unglycosylated isolated and purified recombinant polypeptides comprising a fusion protein able to bind to autoantibodies produced in response to an autoimmune disease associated with an immune reaction to a TSH-receptor (TSHR). Also disclosed are methods of detecting and/or quantifying such autoantibodies using the isolated and purified recombinant polypeptides and respective kits. | 2008-12-11 |
| 20080305099 | Pharmaceutical Composition, Composition for Screening Therapeutics Preventing and Treating Beta Amyloid Accumulation in Brain Comprising Gcp II (Glutamate Carboxypeptidase II) as an Active Ingredient and Method for Screening Using the Same - The present invention relates to a pharmaceutical composition for the prevention and treatment for β-amyloid(Aβ) accumulation in brain comprising GCP-II (Glutamate carboxypeptidase-II) as an active ingredient, a composition for screening method of the same. GCP-II of the present invention not only degrades Aβ monomer and oligomer but also degrades soluble Aβ and insoluble Aβ, particularly aggregated Aβ, so that it can prevent the accumulation of Aβ in brain or reduce the accumulation, making it an excellent candidate for the therapeutic agent for Alzheimer's disease and Down's syndrome. | 2008-12-11 |
| 20080305100 | Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain - Activated protein C (APC), a prodrug, and/or a variant of APC may be used to inhibit undesirable effects of plasminogen activator: e.g., apoptosis or cell death of neurons and endothelial cells, brain hemorrhage or intracerebral bleeding, and/or tissue damage in a subject's brain. Inhibition appears to act through the extrinsic pathway of death receptor signal transduction. This represents an improvement in treatment using plasminogen activator (e.g., fibrinolysis). By reducing undesirable effects, the window for fibrinolytic therapy by plasminogen activator may be widened. | 2008-12-11 |
| 20080305101 | Methods and Compositions Related to Clot Binding Compounds - Disclosed are compositions and methods related to clot binding compounds. The disclosed targeting is useful for treatment of cancer and other diseases and disorders. | 2008-12-11 |
| 20080305102 | Therapeutic Agent for Cancer Comprising Substance Capable of Inhibiting Expression or Function of Synoviolin as Active Ingredient and Screening Method for the Therapeutic Agent for Cancer - Inhibition of synoviolin function was found to activate the cancer-suppressing protein p53. Substances inhibiting the function of synoviolin are useful as cancer therapeutic agents. The inhibition of synoviolin function was also found to lead to the inhibition of p53 ubiquitination, increased activity of p53 phosphorylation proteins, and the like. Based on these findings, the present invention provides methods capable of efficiently screening for cancer therapeutic agents. Further, it was also found that regulation of the autoubiquitination of synoviolin protein suppresses the proliferation of rheumatoid arthritis synovial cells. Substances regulating the autoubiquitination of synoviolin protein are useful as anti-rheumatic agents. Moreover, the present invention provides methods of efficiently screening for anti-rheumatic agents. | 2008-12-11 |
| 20080305103 | Intraocular pressure-regulated early genes and uses thereof - The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 macgroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or α2 macgroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or α2 macgroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins. | 2008-12-11 |
| 20080305104 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 - This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 2008-12-11 |
| 20080305105 | BISPECIFIC ANTIBODIES - The present invention discloses bispecific antibodies comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, the first portion consisting of one antibody variable domain, and a second portion of the bispecific antibody specifically binding to a target antigen other than the effector antigen, the target antigen on a target cell other than the human immune effector cell, the second portion comprising one antibody variable domain. | 2008-12-11 |
| 20080305106 | Novel Gene Disruptions, Composition and Methods Relating Thereto - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO256, PRO34421, PRO334, PRO770, PRO983, PRO1009, PRO1107, PRO1158, PRO1250, PRO1317, PRO4334, PRO4395, PRO49192, PRO9799, PRO21175, PRO19837, PRO21331, PRO23949, PRO697 or PRO1480 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 2008-12-11 |
| 20080305107 | NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE - Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment. | 2008-12-11 |
| 20080305108 | Peptides of Il1 Beta and Tnf Alpha and Method Treatment - The present invention relates to peptides derived from the proinflammatory cytokines, interleukin-1β, (IL1β) and tumor necrosis factor α, (TNFα), and their use in human or veterinary therapy, such as to generally treat diseases linked to the overproduction of IL1β or TNFα as well as acute or chronic inflammatory diseases, rheumatoid arthritis, septic shock, autoimmune diabetes, graft rejection in the host, etc. | 2008-12-11 |
| 20080305109 | Method of passive immunization - This invention relates to compositions and methods which provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections. More particularly it relates to peptides derived from homologous sequences of the family of staphylococcal and streptococcal toxins, which may be polymeric, and carrier-conjugates thereof. The invention also relates to serum antibodies induced by the peptides and carrier-conjugates and their use to prevent, treat, or protect against the toxic effects of most, if not all, of the staphylococcal and streptococcal toxins. | 2008-12-11 |
| 20080305110 | Novel Ligand of G Protein Coupled Receptor Protein and Use Thereof - The present invention provides a method of screening an agonist or antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or a salt thereof and the ligand or a salt thereof; etc. The present invention is useful for screening agents for the prevention/treatment of, e.g., leukopenia, leukemia, lymphoma, malignant tumor, ulcerative colitis, rheumatoid arthritis, inflammatory bowel disorders, tonsil disorders, collagen disease, inflammatory disease, leukocytosis, heart failure, inherited muscle disorders, muscular dystrophy, neuromuscular degenerative disease, myocardial infarction, obesity, mellitus diabetes, hyperlipemia, arteriosclerosis, metabolic syndrome, thrombocytopenia, thrombocytosis, cancer, pulmonary edema, multiple organ failure, etc. | 2008-12-11 |
| 20080305111 | Anti-C35 antibodies for treating cancer - The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and a chemotherapeutic agent. In some preferred embodiments, two C35 antibodies are administered with a chemotherapeutic agent. The present invention is further directed to C35 antibodies useful in these methods. | 2008-12-11 |
| 20080305112 | IMMUNISATION AGAINST CHLAMYDIA TRACHOMATIS - The present invention provides antigenic proteins of | 2008-12-11 |
| 20080305113 | Pharmaceutical Composition for Preventing or Treating Chronic Graft-Versus-Disease Comprising Anti-CD137 Monoclonal Antibody - Provided is a pharmaceutical composition for preventing and treating chronic graft-versus-host disease (cGVHD) containing an anti-CD137 monoclonal antibody. | 2008-12-11 |
| 20080305114 | HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING - Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention. | 2008-12-11 |
| 20080305115 | Reduced-mass, long-acting dosage forms - Methods and compositions are disclosed whereby free antibody or nucleic acid co-administered with a long-acting formulation, such as a microparticle or implant, containing the antibody or nucleic acid to achieve a long duration of antibody or nucleic acid release. One result is that less of the long-acting formulation excipient or polymer is needed allowing for small-volume administrations as required, for example, for ocular, intra-dermal, orthopedic, brain and spinal delivery. In one aspect, the free antibody or nucleic acid alone has efficacy for an extended period, during which time, very little or no long-acting formulation antibody or nucleic acid is released. In one aspect, after the free antibody or nucleic acid has diminished activity, is gone, or no longer has activity, the long-acting formulation antibody or nucleic acid begins to release for a desired preprogrammed duration to provide long-acting durations. Less formulation mass is needed because the entire antibody or nucleic acid is not encapsulated or implanted with encapsulation or implant excipient or polymer. In addition, more antibody or nucleic acid can be administered to afford longer-acting formulations. | 2008-12-11 |
| 20080305116 | Anti-Cd154 Antibodies - The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject. | 2008-12-11 |
| 20080305117 | Kir-Binding Agents and Methods of Use Thereof - The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided. | 2008-12-11 |
| 20080305118 | Treatment Of Type 1 Diabetes With Inhibitors Of Macrophage Migration Inhibitory Factor - Methods of treating a mammal having type 1 diabetes or a risk for type 1 diabetes are provided. The methods comprise administering to the mammal a pharmaceutical composition comprising an agent that inhibits MIF in the mammal. Also provided are methods of evaluating whether a compound is useful for preventing or treating type 1 diabetes. The methods comprise determining whether the compound inhibits a macrophage migration inhibitory factor (MIF) in a mammal, then, if the compound inhibits the MIF, determining whether the compound inhibits development of type 1 diabetes. | 2008-12-11 |
| 20080305119 | Modified Bacteriophage Vectors and Uses Thereof - Provided herein are modified phage surface polypeptides, phages with modified surface polypeptides, nucleic acids that encode the modified surface polypeptides, and related vectors and phages comprising the vectors. The provided phage surface polypeptides optionally comprise one or more modifications, including, for example, one or more modifications to enhance targeting to an antigen-presenting cell and one or more modifications that destabilize a viral capsid. Further provided herein are methods of making a lambda phage with a modified surface polypeptide and methods of making a lambda phage with a plurality of modified surface polypeptides. Also provided herein are antigen delivery systems comprising the modified phages of the invention and methods of promoting an antigenic response in a subject by administering to the subject the antigen delivery system of the invention, alone or in combination with other immunization modalities. | 2008-12-11 |
| 20080305120 | Immunogenic Compositions Comprising Hmgb 1 Polypeptides - The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specially, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation. | 2008-12-11 |
| 20080305121 | Agents for Regulating the Activity of Interferon-Producing Cells - The present invention provides agents for regulating the activity of interferon-producing cells (IPCs), which comprise as active ingredients antibodies that bind to BST2 and/or to its homologues, and methods for regulating IPC activity that use these antibodies. According to the present invention, the ability of IPCs to produce interferons (IFNs) and the number of cells can be directly regulated. The present invention also provides uses of BST2 and/or its homologues as markers for IPC activation. Compounds that regulate IPC activation can be screened using the markers for IPC activation. | 2008-12-11 |
| 20080305122 | Ii-Key/antigenic epitope hybrid peptide vaccines - Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less. | 2008-12-11 |
| 20080305123 | Functional Epitopes of Streptococcus Pneumoniae PsaA Antigen and Uses Thereof - Provided is a P4 peptide, which contains functional epitopes of the PsaA protein of | 2008-12-11 |
| 20080305124 | ORAL PERTUSSIS VACCINE AND METHOD FOR PRODUCING PERTUSSIS VACCINE - The present invention is related to an oral pertussis vaccine and a method for producing pertussis vaccine, wherein the oral pertussis vaccine comprises amino acid sequence of 1094 to 1279 (SEQ ID NO.1) of filamentous hemagglutinin. The method for producing pertussis vaccine comprises following steps: constructing a vector comprising amino acid sequence of 1094 to 1279 (SEQ ID NO. 1) of filamentous hemagglutinin; transforming the vector into | 2008-12-11 |
| 20080305125 | Mutant Forms Of EtxB and CtxB And Their Use As Carriers - The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB. | 2008-12-11 |
| 20080305126 | Separation of Unconjugated and Conjugated Saccharide by Solid Phase Extraction - The invention is based on the use of solid phase extraction for separating conjugated saccharide from unconjugated saccharide in sample, e.g. a vaccine. Solid phase extraction (SPE) provides faster and more reproducible separation of conjugated saccharides from unconjugated saccharides, thereby allowing quantitative separation of these saccharides. The separation of conjugated and unconjugated saccharide using SPE may be advantageously combined with a quantitative conjugate analysis to provide improved quality control for conjugate vaccines. The SPE separation is compatible with existing quantitative conjugate analysis techniques, such as high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD). | 2008-12-11 |
| 20080305127 | Conjugate Vaccines - The invention provides vaccines against | 2008-12-11 |
| 20080305128 | TREATMENT OF PRDC IN PIGS - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 2008-12-11 |
| 20080305129 | Highly Attenuated Pox Virus Strains, Method for the Production Thereof and the Use Thereof as Paramunity Inducers or For Producing Vector Vaccines - The present invention relates to highly attenuated animal smallpox viral strains and to the use thereof as paramunity inducers or for producing vector vaccines. As a result of the high attenuation process, the claimed animal smallpox strains lose their virulent and immunising properties. The invention also relates to a method for producing such highly attenuated pox virus strains and the use thereof for inducing paramunity, i.e. for activating the non-specific immune system in mammals and humans or for producing vector vaccines for specific immunisation with the positive side-effect of paramunisation. The claimed highly attenuated animal smallpox viruses are thus suitable for preventing and treating diseases associated with an immune deficiency. Preferred embodiments relate to highly attenuated orthopox—(e.g. camel smallpox viruses), leporipox—(e.g. myxoma viruses), avipox-, parapox- and other orthopox viral strains, such as MVA, which have excellent paramunisation properties and in which the immunising properties have been lost. | 2008-12-11 |
| 20080305130 | Marked Bovine Viral Diarrhea Virus Vaccines - The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of infectious virus is retained. The present invention is useful, for example, to produce a marked bovine viral diarrhea virus vaccine or to differentiate between vaccinated and infected or unvaccinated animals. | 2008-12-11 |
| 20080305131 | Cancer Immunotherapy with Semi-Allogeneic Cells - The present invention relates to improved semi-allogeneic immunogenic cells which act to stimulate and induce an immunological response when administered to an individual. In particular, it relates to cells which express both allogeneic and syngeneic MHC determinants and which also express at least one antigen recognized by T lymphocytes. The invention is also directed to methods of inducing an immune response and methods of treating tumors by administering the semi-allogeneic immunogenic cells to an individual. | 2008-12-11 |
| 20080305132 | Cosmetic Patch for Skin Treatment - There is provided a treatment product ( | 2008-12-11 |
| 20080305133 | Novel Cosmetic or Dermatological Combinations Comprising Modified Titanium Dioxide Particles - The present invention relates to novel cosmetic or dermatological compositions comprising multiply coated titanium dioxide particles with a water content of less than 1.5%. More particularly, the present invention relates to novel cosmetic or dermatological compositions comprising multiply coated titanium dioxide particles with a water content of less than 1.5% and a dibenzoyl methane derivative. | 2008-12-11 |
| 20080305134 | Treated Bedding Cover - A bedding cover treated with an anti-pest chemical. The cover repels or kills bedbugs, dust mites, ticks, fleas, and other pests for use in bedrooms, hotels, motels, pet beds, and the like. The cover is preferably waterproof and disposable. | 2008-12-11 |
| 20080305135 | Wasp repellents - A method of repelling wasps, which method comprises using a preparation comprising (a) one or more of ethyl 3-(N-n-butyl-N-acetylamino)propionate, dihydronepetalactone, and extract of catmint, and (b) at least one compound selected from certain perfume ingredients. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way. | 2008-12-11 |
| 20080305136 | Disinfective adhesive tape - A disinfective adhesive tape has a carrier layer, a silver nanoparticle layer and an adhesive layer. The carrier layer has a top surface and a bottom surface. The silver nanoparticle layer is formed on the top surface of the carrier layer and comprises multiple silver nanoparticles. The adhesive layer is applied to the bottom surface of the carrier layer. The disinfective adhesive tape can be applied in any article and act as a disinfectant during daily use. | 2008-12-11 |
| 20080305137 | Coating material with biocide microcapsules - The invention relates to a coating material for protection against microorganism invasion on surfaces which are exposed to the effects of damp or water. The coating material has either a pH-value of at least 11.0 or is provide with a base material for the coating whereby the pH-value is at least 11. The coating material is characterized in that it contains a biocide which bonds to solid particles in a carrier material and is released in a delayed manner therefrom. | 2008-12-11 |
| 20080305138 | Photostable Wound Dressing Materials and Methods of Production Thereof - The invention provides a method of preparing an antimicrobial sponge material for medicinal use, comprising the steps of: treating an anionic polysaccharide with a solution of a silver salt to produce a complex of the anionic polysaccharide with silver; dispersing said complex in aqueous ascorbic acid to form an acidified dispersion, followed by freeze-drying or solvent-drying the dispersion to form the sponge material. Also provided is a photostabilized antimicrobial sponge material comprising an anionic polysaccharide complexed with silver (I) ions, wherein the sponge further comprises ascorbic acid, and the sponge has a substantially white colour that is substantially stable against discoloration on exposure to light. Also provided are wound dressings comprising such materials, and the use of such materials in medicine. | 2008-12-11 |
| 20080305139 | Pharmaceutical Compositions Comprising Dextran with a Molecular Weight of 1.0-100 Kda and Processes for Their Preparation - A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for preparing a composition useful for biomedical application, comprising the steps of providing a liquid composition comprising an aqueous solution of dextran having a molecular weight of 1-100 kDa; and bringing the liquid composition to solidify; whereby water is gradually eliminated from the liquid composition during the solidification. A biomedical article prepared from the composition. | 2008-12-11 |
| 20080305140 | Long-Term Delivery Formulations and Methods of Use Thereof - The present invention provides a method, a kit and compositions for long-term release of a drug at a constant therapeutically effective level for nervous system disorders where adherence to therapeutic regimen is problematic. In particular, to the therapy of psychotic disorders. | 2008-12-11 |
| 20080305141 | Freeze-thaw method for modifying stent coating - Methods are disclosed for controlling the morphology and the release-rate of active agent from a coating layer for medical devices comprising a polymer matrix and one or more active agents. The methods comprise exposing a wet or dry coating to a freeze-thaw cycle. The coating layer can be used for controlled delivery of an active agent or a combination of active agents. | 2008-12-11 |
| 20080305142 | Cell Free Biosynthesis of High-Quality Nucleic Acid and Uses Thereof - The invention provides an improved cell free amplification method capable of producing large quantities of therapeutic-quality nucleic acids and methods of using the synthesized nucleic acid in research, therapeutic and other applications—The methods combine several different state-of-the-art procedures and coordinate their applications to affordably synthesize nucleic acids for therapeutic purposes. It combines in vitro rolling circle amplification, high fidelity polymerases, high affinity primers, and streamlined template specifically designed for particular applications. For expression purposes, the templates contain an expression cassette including a eukaryotic promoter, the coding sequence for the gene of interest, and a eukaryotic termination sequence. Following amplification, concatamers are subsequently processed according to their intended use and may include: restriction enzyme digestion for the production of short expression cassettes (SECs); ligation steps to circularize the SEC (CNAs); and/or supercoiling steps to produce sCNAs. The final product contains nearly non-detectable levels of bacterial endotoxin. | 2008-12-11 |
| 20080305143 | Controlled Radical Polymerization-Derived Block Copolymer Compositions for Medical Device Coatings - Controlled radical polymerization-derived biocompatible block copolymer coatings for medical devices are disclosed. Specifically, block copolymer coatings designed to control the release of bioactive agents from medical devices in vivo are disclosed. The present application also discloses providing vascular stents with drug-eluting controlled release block copolymer coatings and related methods for making these medical devices and coatings. | 2008-12-11 |
| 20080305144 | High Strength Devices and Composites - An oriented implantable, biodegradable device is disclosed. The oriented implantable, biodegradable device is formed from a homogeneous polymer blend comprising a polylactic acid in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which both plasticises polymer draw and is a degradation accelerant. The polymer comprised within the blend may be a uniaxial, biaxial or triaxial orientation. Also disclosed is a composite thereof, processes for the preparation thereof, and The implantable biodegradable device may be used as a high strength trauma fixation device suitable for implantation into the human or animal body. As examples, the high strength trauma fixation device may take the form of plates, screws, pins, rods, anchors or scaffolds. | 2008-12-11 |
